id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-275128-620wf0pb	White, J. R.	PI3K/mTOR and topoisomerase inhibitors with potential activity against SARS-CoV-2 infection	2020-09-03		.txt	text/plain	2388	173	47	We performed a statistical evaluation of in vitro gene expression profiles reflecting exposure to 1,835 drugs, and found topoisomerase inhibitors and PI3K/mTOR pathway inhibitors among the strongest candidates for reduced expression of ACE2, a host gene associated with SARS-CoV-2 infection. We next performed a retrospective review of clinical records to evaluate the frequency of SARS-CoV-2 infection in patients on these ACE2-associated antineoplastics. Retrospective data was obtained from an IRB-approved study of adult cancer patients tested for SARS-CoV-2 receiving active antineoplastic therapy at Memorial Sloan Kettering Cancer Center (MSKCC) during the COVID-19 epidemic period (n=4,040 patients; Table S2 ). Patients receiving ACE2-associated therapies demonstrated a lower univariate odds ratio (0.65, 95% CI 0.00-0.98, P=0.04) for a positive SARS-CoV-2 test during active antineoplastic therapy compared to patients on other agents (Table S3) . Cancer patients taking these potential ACE2-associated agents showed lower rates of a positive SARS-CoV-2 test compared to patients taking other forms of active antineoplastic therapy.	./cache/cord-275128-620wf0pb.txt	./txt/cord-275128-620wf0pb.txt